Disease | myoclonus epilepsy |
Comorbidity | C0014544|epilepsy |
Sentences | 10 |
PubMedID- 24027645 | Levetiracetam is an established second-generation antiepileptic drug that is approved as a treatment of partial seizures; other indications include adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures associated with generalized epilepsy. |
PubMedID- 21395360 | Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizures with or without secondary generalization, and adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic (gtc) seizures associated with idiopathic generalized epilepsy. |
PubMedID- 24009559 | At present, lev is a worldwide commonly used second generation aed, approved as adjunctive and monotherapy treatment of partial-onset seizures with or without secondary generalization, and adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy (lyseng-williamson, 2011). |
PubMedID- 22464827 | In only two cases, epilepsy started with myoclonic seizures, and spasms were never observed. |
PubMedID- 22787620 | This chapter presents recent works on myocloni1/ efhc1 a protein encoded by an epilepsy causing gene of juvenile myoclonic epilepsy (jme), one of the most frequent forms of idiopathic or genetic generalized epilepsies. |
PubMedID- 24893590 | The natural history of senile myoclonic epilepsy is consistent with progressive myoclonus epilepsy. |
PubMedID- 22580373 | Late-onset temporal lobe epilepsy in a patient with juvenile myoclonic epilepsy. |
PubMedID- 25667841 | Levetiracetam [(s)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide] (lev) is a second generation anticonvulsant approved by the european medicines agency (ema) and/or the u.s. food and drug administration (fda) for the following: 1) monotherapy treatment of partial seizures, with or without secondary generalization (ema); 2) adjunctive treatment of partial seizures, with or without secondary generalization (fda/ema); 3) adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy (fda/ema); and 4) adjunctive treatment of primary generalized tonic–clonic seizures associated with idiopathic generalized epilepsy (fda/ema) [1,2]. |
PubMedID- 21936590 | Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizures with or without secondary generalization, and adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic (gtc) seizures associated with idiopathic generalized epilepsy. |
PubMedID- 23458465 | Herein i discuss two main variants: that related to temporal lobe epilepsy and that associated with juvenile myoclonic epilepsy. |
Page: 1